[go: up one dir, main page]

TN2013000237A1 - Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor - Google Patents

Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Info

Publication number
TN2013000237A1
TN2013000237A1 TNP2013000237A TN2013000237A TN2013000237A1 TN 2013000237 A1 TN2013000237 A1 TN 2013000237A1 TN P2013000237 A TNP2013000237 A TN P2013000237A TN 2013000237 A TN2013000237 A TN 2013000237A TN 2013000237 A1 TN2013000237 A1 TN 2013000237A1
Authority
TN
Tunisia
Prior art keywords
quinolin
imidazo
compound
kinase
dual inhibitor
Prior art date
Application number
TNP2013000237A
Other languages
English (en)
Inventor
David Anthony Barda
Mary Margaret Mader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TN2013000237A1 publication Critical patent/TN2013000237A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2013000237A 2011-01-14 2013-06-03 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor TN2013000237A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14
PCT/US2012/020897 WO2012097039A1 (fr) 2011-01-14 2012-01-11 Composé d'imidazo[4,5-c]quinolin-2-one et son utilisation comme inhibiteur double de kinase pi3/mtor

Publications (1)

Publication Number Publication Date
TN2013000237A1 true TN2013000237A1 (en) 2014-11-10

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000237A TN2013000237A1 (en) 2011-01-14 2013-06-03 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Country Status (39)

Country Link
US (2) US8440829B2 (fr)
EP (1) EP2663564B1 (fr)
JP (1) JP5891247B2 (fr)
KR (1) KR101561360B1 (fr)
CN (1) CN103282364B (fr)
AR (1) AR084551A1 (fr)
AU (1) AU2012205619B2 (fr)
BR (1) BR112013017672A2 (fr)
CA (1) CA2824760C (fr)
CL (1) CL2013002005A1 (fr)
CO (1) CO6731133A2 (fr)
CR (1) CR20130289A (fr)
CY (1) CY1116007T1 (fr)
DK (1) DK2663564T3 (fr)
DO (1) DOP2013000158A (fr)
EA (1) EA022163B1 (fr)
EC (1) ECSP13012764A (fr)
ES (1) ES2531891T3 (fr)
GT (1) GT201300180A (fr)
HR (1) HRP20150135T1 (fr)
HU (1) HUE024426T2 (fr)
IL (1) IL227165A (fr)
JO (1) JO3003B1 (fr)
ME (1) ME02019B (fr)
MX (1) MX2013008185A (fr)
MY (1) MY164705A (fr)
PE (1) PE20140864A1 (fr)
PH (1) PH12013501493A1 (fr)
PL (1) PL2663564T3 (fr)
PT (1) PT2663564E (fr)
RS (1) RS53828B1 (fr)
SG (1) SG191744A1 (fr)
SI (1) SI2663564T1 (fr)
SV (1) SV2013004496A (fr)
TN (1) TN2013000237A1 (fr)
TW (1) TWI518086B (fr)
UA (1) UA109921C2 (fr)
WO (1) WO2012097039A1 (fr)
ZA (1) ZA201304757B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
SG11201803903YA (en) * 2015-12-15 2018-06-28 Lilly Co Eli Combination therapy for cancer
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
RU2754452C2 (ru) * 2016-04-12 2021-09-02 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
RU2747788C2 (ru) * 2016-04-12 2021-05-14 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
WO2017200969A1 (fr) 2016-05-20 2017-11-23 Eli Lilly And Company Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
WO2018017410A1 (fr) 2016-07-22 2018-01-25 Eli Lilly And Company Polythérapie à base d'abemaciclib et d'un inhibiteur double de kinase pi3 /mtor, destinée à être utilisée dans le traitement du cancer du sein
WO2018063873A1 (fr) * 2016-09-27 2018-04-05 Eli Lilly And Company Polythérapie à base d'abémaciclib et d'un inhibiteur double de kinase pi3/mtor destinée à être utilisée dans le traitement du cancer du pancréas
CA3039405A1 (fr) 2016-10-12 2018-04-19 Eli Lilly And Company Traitement cible de lymphome a cellules t matures
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
EP3706754A1 (fr) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
WO2019157516A1 (fr) 2018-02-12 2019-08-15 resTORbio, Inc. Polythérapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN112423843B (zh) 2018-06-15 2023-11-28 詹森药业有限公司 雷帕霉素类似物和其用途
WO2020081329A1 (fr) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Méthodes et compositions pour moduler l'expression de pcsk9 et d'angptl3
WO2021113665A1 (fr) 2019-12-05 2021-06-10 Navitor Pharmaceuticals, Inc. Analogues de la rapamycine et leurs utilisations
WO2022060377A1 (fr) * 2020-09-21 2022-03-24 Wei Zhong Composés substitués de 1-(3,3-difluoropipéridin-4-yl)-imidazo[4,5-c]quinoléin-2-one présentant une aptitude à traverser la barrière hémato-encéphalique
EP3992191A1 (fr) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Dérivés d'imidazo[4,5-c]quinoline et leur utilisation en tant qu'inhibiteurs de kinase atm
IL313660A (en) 2021-12-22 2024-08-01 Camp4 Therapeutics Corp Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2628131C (fr) 2005-11-04 2012-03-20 Coley Pharmaceutical Group, Inc. 1h-imidazoquinolines substituees par hydroxy et alcoxy et procedes correspondants
WO2007106854A2 (fr) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. 1h-imidazonaphthyridines hydroxy et alcoxy substituées, et procédés associés
CA2735932C (fr) 2008-09-30 2013-07-09 Pfizer Inc. Composes d'imidazo[1,5]naphtyridine, leur utilisation pharmaceutique et compositions associees
NZ596487A (en) 2009-06-04 2012-11-30 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
CA2766967A1 (fr) * 2009-06-30 2011-01-06 Piramal Life Sciences Limited Derives d'imidazo[4,5-c]quinoleine et leur utilisation dans le traitement de tumeurs et/ou d'une inflammation
AR084731A1 (es) * 2010-12-06 2013-06-05 Piramal Life Sciences Ltd Derivados de imidazoquinolina sustituidos
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
PT2663564E (pt) 2015-02-24
PL2663564T3 (pl) 2015-05-29
MX2013008185A (es) 2013-08-21
ECSP13012764A (es) 2013-09-30
CA2824760C (fr) 2016-03-15
RS53828B1 (sr) 2015-06-30
ES2531891T3 (es) 2015-03-20
IL227165A (en) 2016-06-30
US8658668B2 (en) 2014-02-25
UA109921C2 (uk) 2015-10-26
HRP20150135T1 (xx) 2015-03-13
AR084551A1 (es) 2013-05-22
HUE024426T2 (en) 2016-01-28
CO6731133A2 (es) 2013-08-15
ZA201304757B (en) 2014-12-23
SG191744A1 (en) 2013-08-30
HK1188454A1 (en) 2014-05-02
US20130237562A1 (en) 2013-09-12
KR20130116302A (ko) 2013-10-23
CY1116007T1 (el) 2017-01-25
CN103282364A (zh) 2013-09-04
EA201390823A1 (ru) 2013-12-30
CL2013002005A1 (es) 2013-12-27
US20120184577A1 (en) 2012-07-19
PE20140864A1 (es) 2014-07-19
BR112013017672A2 (pt) 2018-09-18
CN103282364B (zh) 2015-06-17
DK2663564T3 (en) 2015-01-12
US8440829B2 (en) 2013-05-14
SI2663564T1 (sl) 2015-01-30
NZ611541A (en) 2015-02-27
TWI518086B (zh) 2016-01-21
AU2012205619B2 (en) 2015-05-21
GT201300180A (es) 2014-04-08
CR20130289A (es) 2013-10-07
PH12013501493A1 (en) 2021-06-02
JP2014502638A (ja) 2014-02-03
ME02019B (me) 2015-05-20
EA022163B1 (ru) 2015-11-30
EP2663564A1 (fr) 2013-11-20
SV2013004496A (es) 2017-11-07
KR101561360B1 (ko) 2015-10-16
DOP2013000158A (es) 2013-11-30
JO3003B1 (ar) 2016-09-05
WO2012097039A1 (fr) 2012-07-19
JP5891247B2 (ja) 2016-03-22
CA2824760A1 (fr) 2012-07-19
AU2012205619A1 (en) 2013-06-27
TW201307343A (zh) 2013-02-16
MY164705A (en) 2018-01-30
EP2663564B1 (fr) 2014-12-17

Similar Documents

Publication Publication Date Title
TN2013000237A1 (en) Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
PH12013500064A1 (en) Combinations of kinase inhibitors for the treatment of cancer
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
MX2013011332A (es) Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos.
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
WO2012068106A3 (fr) Benxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs procédés d'utilisation et de fabrication
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
WO2012068096A3 (fr) Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs méthodes d'utilisation et de fabrication
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX359207B (es) Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y método de preparación y aplicación del mismo.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
WO2014160177A3 (fr) Inhibiteurs quinazolines de pi3k
TH149217A (th) สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้งคู่สำหรับ Pl3 คิเนส/MTOR
TH149217B (th) สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้ง คู่สำหรับ Pl3 คิเนส/MTOR